## 5 Conclusions and Future Studies  
An insightful review of the literature has led to the collection of information regarding experimental evidence of 18 plants from the Apiaceae family (_Alepidea anatymbica_, _Anmodaucus leucotrichus_, _Anmii visnaga_, _Anethum gravoelens_, _Angelica archangelica_, _Angelica dahurica_, _Angelica furcijuga_, _Angelica keiseki_, _Angelica pubescens_, _Angelica sinensis_, _Apium gravoelens_, _Carum carvi_, _Carum copticum_, _Centella asiatica_, _Coriardrum sativum_, _Daucus carota_, _Liguscium wallichi_, _Petroselinum crispum_) and approximately 19 representatives from the Rosaceae family (_Agrimonia eupatoria_, _Crataegus spp._, _Crataegus aronia_, _Crataegus curisepala_, _Crataegus laevigata_, _Crataegus mexicana_, _Crataegus meyeri_, _Crataegus microphylla_, _Crataegus monogyna_, _Crataegus oxacantha_, _Crataegus orientalis_, _Crataegus pinmatifida_, _Crataegus tantactifolia_, _Fragaria ananssa_, _Malus domestica_, _Malus sylvestris_, _Prunus amygdala_, _Rosa damascena_, _Rubus ideaus_). At the same time, these families include 3820 and 5243 species, for Apiaceae and Rosaceae, respectively. Therefore, it can be concluded that a very small part of the species has been tested for cardiological properties. Some of them are commonly used in traditional medicine, and at the same time have no scientific research in the direction of cardiological properties. Thus, untested species create a broad research perspective for scientists, especially considering that new pathways and therapeutic targets related to the complex etiopathogenesis of cardiovascular diseases are still being discovered, e.g., CB1R (cannabinoid receptor 1) and the endocannabinoid system, affecting blood pressure and heart contractility [207]. This creates new possibilities for the use of plant extracts, which are known for their multidirectional action against diseases with the pathomechanism conditioned by numerous reasons. Among the Apiaceae family, the following species are widely using traditionally and at the same time have insufficient science-based (clinical) evidence: _Coriandrum tordylium_, _Eryngium creticum_, _Ferula narthex_, _Lichtensteinia lacera_, _Pastinaca sativa_, and _Peucedanum galbaum_. As far as the Rosaceae family is concerned, species applied traditionally without sufficient scientific investigation (clinical research) are as follows: _Cerasus vulgaris_, _Filipendula ulmaria_, _Leucosidea serica_, and _Prunus spinosa_. Representatives of the Apiaceae and Rosaceae families are abundant in compounds possessing cardioprotective effects, and simultaneously, the lack of studies on their activity towards heart diseases can be observed, so this creates knowledge gaps and prospects for future research. Numerous studies collected in our review were conducted a long time ago and need to be repeated using modern apparatus as well as current techniques. All the above clearly suggests that particular representatives of the Apiaceae and Rosaceae families can be promising therapeutic agents towards the amelioration of cardiovascular diseases. Taking into consideration that these plants are easily available and inexpensive as well as possess significant therapeutic potential, additional studies regarding clinical effectiveness are required. Providing an explanation of the mechanisms of action and specifying their safety and tolerability are the primary aspects to be considered in order to achieve a more promising curative approach. Animal studies as well as pharmacological and clinical trials are essential for determining the clinical effectiveness of plants used in monotherapy or polytherapy. Conceptualization, R.C. and K.D.S.S. ; writing--original draft preparation, R.C., K.D.S.S., B.K., A.G.-C. and G.S. ; writing--review and editing, R.C. and K.D.S.S. ; supervision, K.D.S.S. All authors have read and agreed to the published version of the manuscript. This research was funded by Ministry of Science and Higher Education in Poland DS45 project of Medical University of Lublin. Not applicable.